BeOne Medicines has announced that the US Food and Drug Administration has granted accelerated approval to Beqalzi (sonrotoclax), a next-generation BCL2 inhibitor, for the treatment of adult patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) who have received at least two prior lines of systemic therapy, including a Bruton’s Tyrosine Kinase (BTK) inhibitor.

Beqalzi has been designed to improve BCL2 inhibition through enhanced potency, selectivity and a pharmacologic profile aimed at delivering improved efficacy, tolerability and convenience compared to other therapies in the same class. The approval marks a milestone for patients with advanced MCL, an aggressive subtype of non-Hodgkin lymphoma with limited treatment options after relapse.

The accelerated approval is based on efficacy and safety data from the Phase 1/2 BGB-11417-201 study, which was presented at the 67th Annual Meeting and Exposition of the American Society of Hematology. The study demonstrated an overall response rate of 52 percent and a complete response rate of 16 percent among treated patients. The median time to response was 1.9 months, while the median duration of response reached 15.8 months at a median follow-up of 11.9 months.

The company said treatment with sonrotoclax monotherapy was generally well tolerated during the trial. Continued approval for the indication will depend on confirmation of clinical benefit in the ongoing confirmatory CELESTIAL-RRMCL trial. The FDA had previously granted Breakthrough Therapy Designation, Fast Track Designation and Orphan Drug Designation to sonrotoclax for this indication.

Michael Wang, Global Principal Investigator of the study and professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, said the approval validates sonrotoclax as a foundational therapy option for mantle cell lymphoma patients who have progressed after BTK inhibitor treatment. He noted that the therapy offers physicians an important new treatment option backed by strong efficacy and tolerability data.

Amit Agarwal, Chief Medical Officer for Hematology at BeOne Medicines, said the approval reinforces the company’s strategy of advancing BCL2 inhibition to improve outcomes in B-cell malignancies and expand therapeutic options for patients.

Mantle cell lymphoma remains a rare but aggressive blood cancer, with approximately 3,300 new cases diagnosed annually in the United States. Although many patients initially respond to therapy, relapse is common, and outcomes tend to worsen after progression on BTK inhibitors. The approval of Beqalzi introduces a new targeted mechanism into the MCL treatment landscape and broadens available treatment choices for patients with advanced disease.

Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation, said the approval represents meaningful progress for patients and families dealing with relapsed or refractory mantle cell lymphoma, particularly those who have exhausted existing therapies.

Beqalzi is already approved in China for relapsed or refractory MCL and for chronic lymphocytic leukaemia/small lymphocytic lymphoma patients previously treated with systemic therapies, including BTK inhibitors. Regulatory review of sonrotoclax for MCL is also underway at the European Medicines Agency and other global regulatory agencies.

In addition to MCL, sonrotoclax has received Fast Track and Orphan Drug designations from the FDA for several other haematological malignancies, including Waldenström macroglobulinemia, multiple myeloma, acute myeloid leukaemia and myelodysplastic syndrome. The therapy is also being evaluated in combination regimens, including with zanubrutinib, for chronic lymphocytic leukaemia, with updated clinical data expected at the 2026 American Society of Clinical Oncology.